Welcome to our dedicated page for Penumbra SEC filings (Ticker: PEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating R&D spend for Penumbra’s Lightning Flash thrombectomy platform or tracking how stroke-care sales trend across 100+ countries can feel like navigating a catheter through tight anatomy. The company’s disclosures span hundreds of pages, and the detail investors need—product line revenue, pipeline milestones, or 510(k) updates—often hides deep inside footnotes.
Stock Titan turns that complexity into clarity. Our AI reads every Penumbra annual report 10-K simplified, each Penumbra quarterly earnings report 10-Q filing, and even the swift Penumbra 8-K material events explained, then extracts what matters. Need Penumbra insider trading Form 4 transactions before market open? We send alerts the moment a Penumbra Form 4 insider transactions real-time hits EDGAR. Wonder how directors are paid? The Penumbra proxy statement executive compensation is summarized in plain English. For fast answers, just ask “understanding Penumbra SEC documents with AI” or “Penumbra earnings report filing analysis” and jump straight to the insight.
What you’ll uncover here:
- Device segment revenue shifts across neurovascular and peripheral vascular markets
- Regulatory milestones that could accelerate sales growth
- Penumbra executive stock transactions Form 4 patterns around product launches
Whether you’re screening for valuation catalysts or monitoring compliance risk, this page delivers every filing—10-K, 10-Q, 8-K, S-8, and more—with real-time updates and AI-powered summaries that explain filing meanings in simple terms. No more PDF scavenging; the critical data on Penumbra SEC filings explained simply is already parsed and ready for decision-making.
Penumbra (NYSE:PEN) filed a Form 4 detailing insider transactions by CEO Adam Elsesser.
- Options exercised: 27,976 shares at $30
- Shares sold: 15,890 at an average ≈$253; gross proceeds ≈$4.0 million
- Ownership after trade: 122,441 direct shares and 577,582 indirect shares via trust (≈700k total)
- Sale magnitude: ~2.3% of post-transaction holdings but above the $1 million materiality threshold
Sales were executed under a pre-arranged Rule 10b5-1 plan tied to option expiration on 09/16/2025, suggesting liquidity and tax-coverage motives rather than discretionary selling.
Form 144 Notice of Proposed Sale filed by Adam Elsesser of Penumbra indicates planned sale of 15,890 shares of common stock with an aggregate market value of $4,026,584.79. The sale is scheduled for June 25, 2025, through Morgan Stanley Smith Barney LLC on the NYSE.
The shares were acquired through a stock option exercise on June 25, 2025, with cash payment. The filing reveals significant recent selling activity by Elsesser over the past 3 months:
- June 11, 2025: 15,910 shares for $4.04M
- May 28, 2025: 16,300 shares for $4.37M
- May 14, 2025: 16,600 shares for $4.95M
- May 7, 2025: 16,650 shares for $4.82M
- April 16, 2025: 16,560 shares for $4.54M
- April 2, 2025: 16,565 shares for $4.51M
Total shares outstanding: 38,725,940. The seller affirms no knowledge of undisclosed material adverse information regarding Penumbra's operations.
Penumbra Director Bridget O'Rourke reported a Form 4 filing disclosing the sale of 50 shares of common stock at a price of $259.78 per share on June 16, 2025. The transaction was executed under a pre-established Rule 10b5-1 trading plan, which provides a safe harbor from insider trading allegations.
Following the transaction, O'Rourke maintains beneficial ownership of 5,373 shares held directly, with a portion subject to vesting restrictions. The filing was submitted on June 28, 2025, within the required reporting timeframe.
- Transaction Type: Sale of Common Stock
- Total Transaction Value: $12,989
- Ownership Form: Direct
- Role: Director
FAQ
What is the current stock price of Penumbra (PEN)?
What is the market cap of Penumbra (PEN)?
What is the core business of Penumbra Inc.?
What type of products does Penumbra offer?
How do Penumbra's products improve clinical outcomes?
In which markets does Penumbra operate?
What sets Penumbra's technology apart from competitors?
How does Penumbra support healthcare providers?
What role does research and development play at Penumbra?
How is the business model of Penumbra structured?
